A new review of preclinical studies suggests GLP-1 drugs like Ozempic may reduce key proteins linked to Alzheimer’s disease.

Drugs best known for helping people lose weight may also chip away at the proteins that define Alzheimer’s disease. A ...

A major review challenges a long-standing strategy in Alzheimer’s research, suggesting that removing a hallmark brain protein ...

Anti-amyloid drugs may not have a clinically meaningful effect in the treatment of Alzheimer's disease, a new review says. So ...

Drugs that target amyloid beta proteins in the brain likely have no clinically meaningful positive effects, while increasing the risk of bleeding and swelling in the brain, a new Cochrane review has ...

Amyloid-beta-targeted monoclonal antibodies had negligible effects for adults with mild cognitive impairment or AD-related dementia.

A major review of 30 preclinical studies suggests GLP-1 receptor agonists, widely used for diabetes and weight loss, may ...

Here’s what researchers want you to know.

A newly published Cochrane systematic review examining amyloid-beta-targeting monoclonal antibodies in Alzheimer's disease ...

Amyloid-beta-targeted monoclonal antibodies probably resulted in little to no difference in cognitive function or in dementia severity.